Biolife Solutions Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
7analysts covering
FY Revenue (est.)
$115.2Mnext fiscal year
FY EPS (est.)
$0.25next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly27.5MTarget: 112500000 to 115000000 (Full Year 2026)
GAAP Gross Margin Quarterly64.0%Target: Mid-60% range
Non-GAAP Adjusted EBITDA Margin Quarterly22.0%Target: Continued expansion of adjusted EBITDA margin (non-GAAP)
Commercially Sponsored US Clinical Trials Market Share Quarterly70.0%Target: Maintain >70% market share
Watch Items
- Manufacturing yield issues affecting gross marginsTrigger: Gross margin dropping below 63%Action: Investigate production processes and supply chain inputs for biopreservation media.
- Customer concentration and clinical trial progressionTrigger: Phase III trial count dropping below 30Action: Re-evaluate customer pipeline and commercial adoption rates of CryoStor and HypoThermosol.
Research as of 19 Jun 2026